1. Introduction {#sec1}
===============

Rheumatoid arthritis (RA) is a common chronic inflammatory disease that is difficult to treat satisfactorily using western medicine \[[@B1]\]. The descriptive epidemiology of RA is suggestive of a genetic effect. The incidence of RA is higher in Europe than in China, with a prevalence of 0.5--1.0% reported in several European countries \[[@B2]--[@B10]\]. As the disease is both chronic and progressive, resultant disabilities and occupational impact pose major clinical challenges \[[@B11], [@B12]\]. In China, 48% of RA patients experience impairments in their work capacity, often in addition to social capacities \[[@B13]\]. In Finland, Netherlands, UK, Canada, and USA, 20--70% of patients become work-disabled within 5--10 years after symptom onset, with a 50% probability within 4.5--22 years \[[@B14], [@B15]\]. At present, effective and cost-effective treatment methods are still urgently required.

*Tripterygium wilfordii* Hook.f. (TWHF) is a traditional Chinese herb grown in the east and south of China, Japan, and Korea \[[@B16]\]. It has long been used in traditional Chinese medicine, often for rheumatoid arthritis \[[@B17]\]. TWHF has exhibited multiple pharmacological activities, such as anti-inflammatory, immune modulation, antitumor, and antifertility activities \[[@B18]\]. Specifically regarding its use for RA, numerous preclinical studies have demonstrated immune-suppressive, cartilage protective, and anti-inflammatory effects \[[@B19]\]. Currently, several*Tripterygium wilfordii* Hook.f. preparations (TWPs) derived from TWHF extracts are available, including*Tripterygium wilfordii* tablets and*Tripterygium wilfordii* glycosides tablets. However, the clinical application of TWHF is limited by its narrow therapeutic window and potentially severe toxicity toward several organs including liver and kidney \[[@B20]\]. The most frequent side effects of TWHF are gastrointestinal tract disturbances (especially diarrhea), leukopenia, thrombocytopenia, rash, skin pigmentation, and dysfunctions of the male and female reproductive system \[[@B19]\]. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of TWPs in comparison with other western or Chinese medicines to provide more reliable evidence for the further study and clinical application.

2. Methods {#sec2}
==========

2.1. Criteria for Considering Studies for This Review {#sec2.1}
-----------------------------------------------------

### 2.1.1. Inclusion and Exclusion Criteria {#sec2.1.1}

Studies that met the following criteria were included in the review: (1) published in English or Chinese language; (2) randomized or quasirandomized clinical trial; (3) participating patients having a confirmed diagnosis of RA; (4) TWPs of any kind being used.

Studies that met the following criteria were excluded: (1) randomized crossover trials, case reports, case series, reviews, qualitative studies, or animal experiments; (2) participants being restricted to special populations (e.g., the elderly, juveniles); (3) TWPs interventions being combined with other internal medicines for RA; (4) interventions being in decoction form, not in processed preparations; (5) studies which used TWPs in both the treatment and control groups.

### 2.1.2. Outcome Measures {#sec2.1.2}

The primary outcomes analyzed in this meta-analysis were effectiveness and adverse events. Effectiveness was calculated from the number of patients cured, markedly improved, and improved. Adverse events were calculated from the number of patients who had adverse events and were used to evaluate the safety of TWPs. Secondary outcomes analyzed for this meta-analysis were erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and C-reactive protein (CRP). All data was taken directly from the original studies.

2.2. Literature Search Strategy {#sec2.2}
-------------------------------

Three Chinese language databases and five English language databases were widely searched for all relevant results until April 10, 2017. The Chinese language databases were China National Knowledge Infrastructure (CNKI), VIP Database (VIP), and Wanfang Data. The five English language databases are PubMed, ScienceDirect, Foreign Medical Retrieval System (FMRS), ClinicalTrials.gov, and Cochrane Library. The literature search strategy used the following terms: English ("*Tripterygium wilfordii* Hook f" OR "lei gong teng" OR "thunder god vine" OR "yellow vine") AND ("rheumatoid arthritis" OR "RA"); and related Chinese ("lei gong teng" OR "huang teng") AND ("lei feng shi guan jie yan" OR "lei feng shi" OR "guan jie yan" OR "bi zheng" OR "wang bi" OR "jiu bi" OR "li jie" OR "lei feng shi xing guan jie yan").

2.3. Data Collection and Analysis {#sec2.3}
---------------------------------

### 2.3.1. Data Extraction and Management {#sec2.3.1}

Both groups of reviewers (WJ and CN) independently extracted data from the original articles. After checking, any disagreements were settled by discussion between the two groups. All the data were recorded using a data collection form. The form contents were as follows: Source, Eligibility, Methods (study design, total study duration, sequence generation, allocation sequence concealment, and blinding, other concerns about bias), Participants (total number, setting, diagnostic criteria, age, sex, and country), Interventions and controls (total number, specific details), Outcomes (time points, outcome definition, and unit of measurement), Results (number of participants, sample size, missing participants, and summary data), and Miscellaneous information. The collected outcome data was inputted into Review Manager 5.3 (RevMan5.3).

### 2.3.2. Assessment of Risk of Bias {#sec2.3.2}

Assessment of risk of bias was based on random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other potential sources of bias. Criteria for judging risk of bias were taken from the "risk of bias" assessment tool in The Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. Studies were assessed as "low risk," "unclear risk," or "high risk," with the last category indicating either lack of information or uncertainty over the potential for bias. This judgement was evaluated by two groups (WJ and CN) independently, and disagreements were resolved by a third group (ZXP).

### 2.3.3. Assessment of Heterogeneity {#sec2.3.3}

Heterogeneity was assessed by visually inspecting forest plots and formally estimated by Cochran\'s *Q* test, in which chi-square distribution is used to make inferences regarding the null hypothesis of homogeneity (*P* \< 0.10 was deemed to be representative of statistically significant heterogeneity). We also quantified heterogeneity with *I*^2^ statistic, which measures the degree of inconsistency in the studies by calculating what percentage of the total variation across studies is due to heterogeneity rather than chance. Interpretation is as follows: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; 75% to 100% may represent considerable heterogeneity. The importance of the observed value of *I*^2^ depends on the magnitude and direction of effects and the strength of evidence for heterogeneity. A fixed effects model was used when *I*^2^ \< 50%; otherwise the random effects model was used.

### 2.3.4. Data Synthesis {#sec2.3.4}

We used RevMan 5.3 for statistical analysis. The extracted data were divided into dichotomous and continuous variables. Data were summarized using risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes; mean difference (MD) with 95% CI was presented for continuous outcomes.

### 2.3.5. Sensitivity Analysis {#sec2.3.5}

For different outcome measures, we investigated possible clinical causes by conducting subgroup and sensitivity analyses. Various subgroup analyses were performed based on types of medication. Sensitivity analyses were performed by removing each study in sequence and recalculating the results, aiming to assess whether one or more of the studies influenced the overall results.

3. Results {#sec3}
==========

3.1. Results of the Search {#sec3.1}
--------------------------

The database search obtained 1382 potentially relevant records (1155 records from Chinese databases and 227 records from English databases). 1063 records remained after removal of duplicates. A total of 924 trials were excluded after reading of the titles and abstracts, due to lack of relevance. The full texts of the remaining 139 articles were read and analyzed in detail, with 14 papers finally included for the systematic review. However, 3 of them did not have the available data and were thus also excluded. This screening process is summarized in a flow diagram ([Figure 1](#fig1){ref-type="fig"}).

3.2. Study Characteristics {#sec3.2}
--------------------------

The included studies were published between 2009 and 2016. Ten studies were published in Chinese, while one \[[@B21]\] study was in English. All of the randomized controlled trials (RCTs) originated in China and demonstrated no significant difference between control and treatment groups in baseline characteristics. Mean age ranged between 35.8 and 51.3 years, although two studies \[[@B22], [@B23]\] did not mention age. Mean disease duration ranged from 42 to 120 months, though was unmentioned in three studies \[[@B22]--[@B24]\]. Ten studies used the 1987 American Rheumatism Association (ARA 1987) diagnostic criteria, including one \[[@B22]\] combined with the ACR 2009 and the European League Against Rheumatism (2009 ACR/EULAR), while one \[[@B21]\] used the ACR 2010 and the European League Against Rheumatism (2010 ACR/EULAR) criteria. Five \[[@B21]--[@B23], [@B25], [@B26]\] studies were aimed at active RA, while six studies were not or did not mention it. Eight studies compared TWPs treatment with conventional western medicine, Leflunomide (LEF) \[[@B22], [@B25], [@B26]\], Methotrexate (MTX) \[[@B21], [@B23], [@B24], [@B27]\], and Diclofenac Sodium Sustained Release Capsules (DSSRC) \[[@B24], [@B28]\], one \[[@B29]\] compared it to placebo, and two \[[@B30], [@B31]\] compared it with other Chinese patent medicines. Eight studies reported participant withdrawal and adverse effects, while three \[[@B23], [@B26], [@B31]\] did not. The study characteristics are shown in [Table 1](#tab1){ref-type="table"}.

3.3. Risk of Bias {#sec3.3}
-----------------

Six \[[@B21], [@B23], [@B25], [@B26], [@B29], [@B31]\] of the included articles described the specific method of randomization. Four \[[@B23], [@B25], [@B29], [@B31]\] of them described the allocation concealment method. Four \[[@B21], [@B23], [@B25], [@B29]\] of them stated clearly that participants and personnel were blinded. Six \[[@B22], [@B25]--[@B27], [@B29], [@B31]\] of them stated blinding of outcome assessment clearly. Only one \[[@B25]\] had incomplete outcome data. Five \[[@B22], [@B23], [@B26], [@B29], [@B31]\] studies lacked data for some of our reviewed outcomes. The risk of bias is shown in [Figure 2](#fig2){ref-type="fig"}.

3.4. Effects of Interventions {#sec3.4}
-----------------------------

### 3.4.1. Effectiveness {#sec3.4.1}

Seven studies evaluated the effectiveness of TWPs with 950 patients in the TWPs group and 516 patients in the control group. Our analysis revealed that TWPs can increase effectiveness compared with the control group (RR: 1.20; 95% CI: 1.13--1.27;*P*\< 0.00001). As homogeneity might not be important in the trial results (*χ*^2^ = 8.73;*P*= 0.19; *I*^2^ = 31%), a fixed effects model was applied ([Figure 3](#fig3){ref-type="fig"}). Sensitivity analyses were performed to assess the stability of the meta-analysis. The RR ranged from 1.18 to 1.25, indicating a good stability of the meta-analysis ([Table 2](#tab2){ref-type="table"}). Subgroup analyses were divided into a conventional western medicine (CWM) group and a Chinese patent medicine or placebo (COP) group. The result of subgroup analysis revealed that TWPs can increase effectiveness compared with the CWM group (RR: 1.16; 95% CI: 1.09--1.24;*P*\< 0.0001), as well as the COP group (RR: 1.32; 95% CI: 1.18--1.47;*P*\< 0.00001) ([Figure 4](#fig4){ref-type="fig"}).

### 3.4.2. Adverse Events {#sec3.4.2}

Eight studies evaluated the effectiveness of TWPs with 478 patients in the TWPs group and 482 patients in the control group. Our analysis revealed that TWPs can decrease adverse events compared with the control group (RR: 0.82; 95% CI: 0.70--0.97;*P*= 0.02). As the homogeneity might not be important in the trial results (*χ*^2^ = 5.99;*P*= 0.54; *I*^2^ = 0%), a fixed effects model was applied ([Figure 3](#fig3){ref-type="fig"}). The RR ranged from 0.80 to 0.86, indicating a good stability of the meta-analysis ([Table 2](#tab2){ref-type="table"}). The result of subgroup analysis revealed that TWPs can decreases adverse events compared with the CWM group (RR: 0.08; 95% CI: 0.67--0.95;*P*= 0.01), but there was no strong evidence in comparing with the COP group (RR: 1.60; 95% CI: 0.64--4.00;*P*= 0.32) ([Figure 4](#fig4){ref-type="fig"}).

### 3.4.3. ESR {#sec3.4.3}

Nine studies evaluated ESR of TWPs with 950 patients in the TWPs group and 516 patients in the control group. Our analysis revealed that TWPs can decrease the ESR compared with the control group (MD: −3.59; 95% CI: −6.72--−0.46;*P*= 0.02). As the homogeneity may represent substantial heterogeneity in the trial results (*χ*^2^ = 14.38;*P*= 0.0006; *I*^2^ = 71%), a random effects model was applied ([Figure 3](#fig3){ref-type="fig"}). The MD ranged from −3.15 to −4.09, indicating a good stability of the meta-analysis ([Table 2](#tab2){ref-type="table"}).

### 3.4.4. RF {#sec3.4.4}

Three studies evaluated RF of TWPs with 197 patients in the TWPs group and 202 patients in the control group. Our analysis revealed that TWPs can decrease the RF compared with the control group (MD: −5.41; 95% CI: −7.46--−3.37;*P*\< 0.00001). As the homogeneity might not be important in the trial results (*χ*^2^ = 2.31;*P*= 0.31; *I*^2^ = 13%), a fixed effects model was applied ([Figure 3](#fig3){ref-type="fig"}). The sensitivity analysis showed that MD ranged from −5.41 to 5.46, indicating not a good stability of the meta-analysis ([Table 2](#tab2){ref-type="table"}).

### 3.4.5. CRP {#sec3.4.5}

Seven studies evaluated CRP of TWPs with 405 patients in the TWPs group and 411 patients in the control group. Our analysis revealed that TWPs can decrease the CRP compared with the control group (MD: −1.03; 95% CI: −1.76--−0.29;*P*= 0.006). As the homogeneity may represent substantial heterogeneity in the trial results (*χ*^2^ = 0.33;*P*= 0.01; *I*^2^ = 62%), a random effects model was applied ([Figure 3](#fig3){ref-type="fig"}). The sensitivity analysis showed that MD ranged from −0.77 to −1.22, indicating a good stability of the meta-analysis ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

This meta-analysis included 11 RCTs with 1675 participants, analyzing the effectiveness, adverse events, serology index RF, and acute phase reactants ESR and CRP. The results of the meta-analysis suggest that patients with RA may benefit from TWPs. TWPs can increase effectiveness by 20%, while decreasing the risk of adverse events by 18%. Improvements in ESR, RF and CRP values were dramatic (resp., 359%, 541% and 103% of the improvements seen in control groups). Subgroup analyses were also used for comparing TWPs versus CWM and TWPs versus COP. These showed that TWPs can increase effectiveness by 16% compared with the CWM group and 32% compared with COP. TWPs can decrease the risk of adverse events by 20% compared with the CWM group, but no strong evidence appeared for a decrease in risk compared with COP.

Previous meta-analyses on TWHF focused on treatment using the whole herb, or its extract, whereas the present analyzed only results from preparations (TWPs). Our results echoed other systematic reviews and meta-analyses that focused on TWHF herbal treatment. TWHF extracts have been found to reduce RA signs and symptoms such as ESR, RF, CRP, grip strength, and 15m walking time, compared to certain drugs or placebos \[[@B32]--[@B35]\]. However, our adverse events comparison differed from Jiang et al. \[[@B34]\], in which the incidence of adverse reactions in*Tripterygium wilfordii* extract (TWE) treatment was higher than with Disease-modifying Antirheumatic Drugs (DMARDs). In contrast, the DMARDs, Leflunomide (LEF) and Methotrexate (MTX), were included in our meta-analysis control group and showed more frequent adverse events than the TWPs group. In our review, the most frequent adverse effects of TWPs were gastrointestinal discomfort, skin and mucous events, and menstruation disorders ([Table 3](#tab3){ref-type="table"}). These frequencies likely differed from Liu et al. \[[@B32]\] as we included a study of a topical agent. Therefore, the skin and mucous events may have not been directly just caused by TWPs, but by other materials used in the topical preparations. Regardless, incidences of skin and mucous events were still lower than the control group in this review. Of course, it may be due to the different trails the two reviews included or to the low quality of the trails the present review included which might have report bias.

In conventional medicine, RA is often managed with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), DMARDs, and biological agents. NSAIDs are unable to modify the long-term course of disease and have toxic gastrointestinal and cardiac effects \[[@B36], [@B37]\]. DMARD use carries risks such as hepatotoxicity, blood dyscrasias, and interstitial lung disease \[[@B38], [@B39]\]. Biological agents are under a higher a priori risk of infection, and the cost-effectiveness of very early intervention remains uncertain \[[@B40], [@B41]\].

Management of rheumatoid arthritis should be effective and affordable \[[@B36]\]. According to Finckh et al.\'s research, the cost-effectiveness ratio of the early DMARD strategy is \$4849 per QALY (quality-adjusted life-year) \[[@B41]\]. As herbal preparations are often cheaper than pharmaceutical drugs, it is likely that TWPs would be a more economical treatment than conventional medicine, and at least effective. If so, introducing TWPs into conventional RA treatment can potentially provide a significant cost-saving measure. A precise estimate of the financial benefit would require the further research.

A few limitations in this meta-analysis should be considered. First, the baseline physical activity of the two groups may be different and may be a potential confounding factor. Second, the results for ESR and CRP have significant heterogeneity, perhaps due to widely varying clinical standards, intervention methods, doses, and duration of treatment. Third, the included studies were in general of poor methodological quality, at times lacking information about random sequence generation, allocation concealment, or blinding of participants, personnel, and outcome assessors. Fourth, the longest follow-up period was 24 weeks, which does not allow analysis of long-term toxicity and more serious adverse events, for example, reversible amenorrhea in women and infertility in men.

Recommendations for future research include higher quality clinical studies with a longer follow-up period. A further meta-analysis comparing TWPs combined with DMARDs to TWPs alone would be a further step to build on present results. The standardization of clinical trial procedures would assist greatly in performing comparisons and meta-analyses. Further research into both potential toxicity of and detoxification from TWPs is needed. Last but not least, an analysis of TWPs\' cost-effectiveness will help inform policy-makers, physicians, and patients.

5. Conclusion {#sec5}
=============

From this meta-analysis, it is evident that TWPs may be efficacious in treating RA with relatively lower toxicity. It is our hope that further research can determine which TWP is the most effective, safe, and cost-effective option for RA patients.
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![Flowchart of the trial selection process.](ECAM2018-1567463.001){#fig1}

![(a) Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies. (b) Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.](ECAM2018-1567463.002){#fig2}

![Forest plot of comparison: TWPs group versus control group. (a) Effectiveness. (b) Adverse events. (c) ESR. (d) RF. (e) CRP.](ECAM2018-1567463.003){#fig3}

![Forest plot of subgroup comparison: TWPs group versus CWM group; TWPs group versus COP group. (a) Effectiveness. (b) Adverse events.](ECAM2018-1567463.004){#fig4}

###### 

Trials characteristics.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID               Group   Age (year)       Disease duration\   Outcomes                                                  Diagnostic criteria   Active or not   Duration (week)   Intervention group   Control group   Withdrawal/adverse effects                                                   
                                                  (months)                                                                                                                                                                                                                                                
  ---------------------- ------- ---------------- ------------------- --------------------------------------------------------- --------------------- --------------- ----------------- -------------------- --------------- ---------------------------- -------------- ----------- -------------------- ---
  Cao, 2015              TWPs\   47.81 (10.37)\   59.39 (67.11)\      ACR 20/50/70, DAS28, ESR, CRP, RF, CCP, GP, VAS, DMS, \   ARA 1987              Y               12                139\                 XFC\            3 tid po\                    143 (27/116)   LEF\        10 mg qd\            Y
                         CWM     48.94 (10.51)    61.80 (65.62)       TJC, SJCHAQ, QLT, SDS, SAS, X ray                                                                                 (17/122)             LEF PLB         10 mg qd po                                 XFC PLB     3 tid                

                                                                                                                                                                                                                                                                                                          

  Jiang et al., 2015     TWPs\   18--75           \-                  VAS, DAS28, AOT, SOT                                      ARA 1987\             Y               12                28                   KXC             2 tid po                     28             LEF         20 mg qd             Y
                         CWM                                                                                                    ACR/EULAR 2009                                                                                                                                                            

                                                                                                                                                                                                                                                                                                          

  Jiao et al., 2016      TWPs\   52 (9)\          120 (96)\           VAS, DAS28, ESR, hs-CRP                                   ARA 1987              \-              8                 87 (6/81)            FFLTA           20 g qd ext                  87 (14/73)     PLB         20 g qd ext          Y
                         PLB     52 (10)          102 (77)                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                          

  Li, 2010               TWPs\   \-               \-                  TJC, SJC, DMS, QLT, ESR, CRP                              ARA 1987              Y               12                33                   LJS\            66 g tid po\                 33             MTX\        15 mg qw po\         N
                         CWM                                                                                                                                                                                 MTX PLB         15 mg qw po                                 LJS PLB     66 g tid po          

                                                                                                                                                                                                                                                                                                          

  Li et al., 2009        TWPs\   44.6 (13.1)\     68.88 (87.12)\      HAQ, DMS, VAS, TJC, SJC, CRP,  \                          ARA 1987              \-              8                 53 (15/38)           STTBW\          4 g bid po\                  54 (12/42)     ZQFTN\      40 mg tid po\        Y
                         CPM     43.6 (14.5)      66.48 (87.48)       ESR, RF                                                                                                                                ZQFTN PLB       40 mg tid po                                STTBW PLB   4 g bid po           

                                                                                                                                                                                                                                                                                                          

  Lv et al., 2014        TWPs\   51.3 (8.3)\      61.9 (81.9)\        PAP, PGADA, PGADA, TJC, SJC, ESR, CRP,  \                 ACR/EULAR 2010        Y               24                69 (13/56)           TWHF pills\     20 mg tid po                 69 (10/59)     MTX         7.5--12.5 mg qw po   Y
                         CWM     51.0 (10.3)      58.8 (88.7)         HAQ, SF-36, DAS28                                                                                                                      MTX                                                                                          

                                                                                                                                                                                                                                                                                                          

  Meng et al., 2013      TWPs\   38.25 (4.43)\    \-                  TJC, SJC, SC, VAS, DMS, MGS, 15 mWT                       ARA 1987              N               12                50 (11/39)           FFLGTYJ         10 ml tid po with honey      50 (9/41)      MTX\        10 mg qw po\         Y
                         CWM     39.33 (3.58)                                                                                                                                                                                                                            DSSRC       50 mg bid po         

                                                                                                                                                                                                                                                                                                          

  Wang, 2004             TWPs\   42.64 (14.52)\   94.44 (28.08)\      DMS, MGS, VAS, SJC, TJC, ESR, CRP, RF, IgG, IgM, IgA      ARA 1987              N               12                6 (3/3)              TWHF pills      10 mg tid po                 6 (2/4)        YSJBW       8 g tid po           N
                         CPM     41.87 (11.96)    91.56 (26.28)                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                          

  Wang et al., 2013      TWPs\   47.43 (8.75)\    67.10 (54.02)\      TJC, SJC, DMS, ESR, CRP, RF, IgG                          ARA 1987              Y               4                 30 (3/27)            XFC             3 tid po                     30 (2/28)      LEF         10 mg qd po          N
                         CWM     43.67 (10.10)    67.93 (56.95)                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                          

  Yang and Zhang, 2007   TWPs\   37.6\            42\                 DMS, TJC, SJC, MGS, 20 mWT, ESR, CRP, RF, IgG, IgM, IgA   ARA 1987              N               4                 60 (18/42)           TWHF pills      20 mg tid po                 60 (16/44)     MTX         15 mg qw po          Y
                         CWM     35.8             45.6                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                          

  Zhou and Yuan, 2013    TWPs\   37.28\           78.24\              DMS, TJC, SJC, MGS, 20 mWT, ESR, CRP, RF                  ARA 1987              N               12                500 (123/377)        LDJ             20 ml tid po                 60 (15/45)     DSSRC       50 mg bid po         Y
                         CWM     37.25            78                                                                                                                                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. TWPs: *Tripterygiumwilfordii* Hook.f. preparations; CWM: conventional western medicine; CPM: Chinese patent medicine; PLB: placebo; N: no; Y: yes; -: not mentioned; XFC: Xin Feng capsules; LEF: Leflunomide; KXC: Kun Xian capsules; FFLTA: Fu Fang Lei Gong Teng topical agent; LJS: Lei Gong Teng Jia Su; MTX: Methotrexate; STTBW: San Teng Tong Bi Wan; ZQFTN: Zheng Qing Feng Tong Ning; TWHF pills: Lei Gong Teng Duo Dai pills; LDJ: Lei Gong Teng Dang Gui wine; YSJBW: Yi Shen Juan Bi Wan; DSSRC: Diclofenac Sodium Sustained Release Capsules; ACR20/50/70: American College of Rheumatology Criteria 20/50/70; DAS28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; CCP: cyclic citrullinated peptide (CCP) antibody; hs-CRP: high-sensitivity CRP; VAS: Visual Analogue Scale; DMS: duration of morning stiffness; TJC: tender joint count; SJC: swollen joint count; MGS: mean grip strength; 15 mWT: 15 m walking time; 20 mWT: 20 m walking time; AOT: analgesic onset time; SOT: swelling onset time; SF-36: short form 36 health questionnaire; HAQ: Health Assessment Questionnaire.

###### 

The results of the included studies through sensitivity analysis.

  Excluded study         TWPs group (number)   Control group (number)   RR/MD (95% CI)           *P* value        Heterogeneity test           Effect model
  ---------------------- --------------------- ------------------------ ------------------------ ---------------- ---------------------------- --------------
  *Effectiveness*                                                                                                                              
  Before excluding       950                   516                      1.20 \[1.13, 1.27\]      *P* \< 0.00001   *P* = 0.19, *I*^2^ = 31%     Fixed
  Cao, 2015              811                   373                      1.25 \[1.16, 1.34\]      *P* \< 0.00001   *P* = 0.86, *I*^2^ = 0%      Fixed
  Jiao et al., 2016      871                   436                      1.18 \[1.10, 1.25\]      *P* \< 0.00001   *P* = 0.37, *I*^2^ = 7%      Fixed
  Li et al., 2009        897                   462                      1.19 \[1.12, 1.26\]      *P*\< 0.00001    *P* = 0.15, *I*^2^ = 38%     Fixed
  Lv et al., 2014        881                   447                      1.20 \[1.13, 1.27\]      *P*\< 0.00001    *P* = 0.12, *I*^2^ = 43%     Fixed
  Meng et al., 2013      900                   466                      1.20 \[1.13, 1.27\]      *P*\< 0.00001    *P* = 0.12, *I*^2^ = 43%     Fixed
  Yang and Zhang, 2007   890                   456                      1.19 \[1.12, 1.26\]      *P* \< 0.00001   *P* = 0.15, *I*^2^ = 38%     Fixed
  Zhou and Yuan, 2013    450                   456                      1.20 \[1.12, 1.28\]      *P*\< 0.00001    *P* = 0.12, *I*^2^ = 43%     Fixed
  *Toxicity*                                                                                                                                   
  Before excluding       978                   542                      0.83 \[0.70, 0.98\]      *P* = 0.03       *P* = 0.54, *I*^2^ = 0%      Fixed
  Cao, 2015              839                   399                      0.80 \[0.65, 0.98\]      *P* = 0.03       *P* = 0.47, *I*^2^ = 0%      Fixed
  Jiang et al., 2015     950                   516                      0.84 \[0.71, 0.99\]      *P* = 0.04       *P* = 0.54, *I*^2^ = 0%      Fixed
  Jiao et al., 2016      899                   462                      0.80 \[0.67, 0.95\]      *P*= 0.009       *P* = 0.85, *I*^2^ = 0%      Fixed
  Li et al., 2009        925                   488                      0.83 \[0.70, 0.99\]      *P*= 0.03        *P* = 0.42, *I*^2^ = 0%      Fixed
  Lv et al., 2014        909                   473                      0.86 \[0.70, 1.05\]      *P* = 0.13       *P* = 0.49, *I*^2^ = 0%      Fixed
  Meng et al., 2013      928                   492                      0.83 \[0.70, 0.99\]      *P*= 0.03        *P* = 0.43, *I*^2^ = 0%      Fixed
  Yang and Zhang, 2007   918                   482                      0.86 \[0.72, 1.02\]      *P* = 0.08       *P* = 0.55, *I*^2^ = 0%      Fixed
  Zhou and Yuan, 2013    478                   482                      0.82 \[0.67, 1.01\]      *P*= 0.06        *P* = 0.43, *I*^2^ = 0%      Fixed
  *ESR*                                                                                                                                        
  Before excluding       985                   531                      −3.59 \[−6.72, −0.46\]   *P* = 0.02       *P* = 0.0006, *I*^2^ = 71%   Random
  Cao, 2015              847                   389                      −4.02 \[−7.37, −0.68\]   *P* = 0.02       *P* = 0.001, *I*^2^ = 71%    Random
  Jiao et al., 2016      906                   471                      −4.46 \[−7.48, −1.44\]   *P* = 0.004      *P* = 0.004, *I*^2^ = 67%    Random
  Li et al., 2009        932                   477                      −3.25 \[−6.97, 0.46\]    *P* = 0.09       *P* = 0.0003, *I*^2^ = 74%   Random
  Lv et al., 2014        916                   462                      −3.22 \[−6.64, 0.21\]    *P* = 0.07       *P* = 0.0003, *I*^2^ = 74%   Random
  Meng et al., 2013      935                   481                      −3.15 \[−7.10, 0.79\]    *P* = 0.12       *P* = 0.0003, *I*^2^ = 74%   Random
  Wang, 2004             979                   525                      −4.02 \[−7.30, −0.73\]   *P* = 0.02       *P* = 0.0008, *I*^2^ = 72%   Random
  Wang et al., 2013      955                   501                      −4.09 \[−7.15, −1.03\]   *P* = 0.009      *P* = 0.001, *I*^2^ = 71%    Random
  Yang and Zhang, 2007   925                   471                      −3.21 \[−6.74, 0.32\]    *P* = 0.08       *P* = 0.0003, *I*^2^ = 74%   Random
  Zhou and Yuan, 2013    485                   471                      −3.38 \[−5.08, −1.69\]   *P* \< 0.0001    *P* = 0.10, *I*^2^ = 41%     Fixed
  *RF*                                                                                                                                         
  Before excluding       197                   202                      −5.41 \[−7.46, −3.37\]   *P* \< 0.00001   *P* = 0.31, *I*^2^ = 13%     Fixed
  Cao, 2015              59                    60                       −5.47 \[−7.51, −3.42\]   *P* \< 0.00001   *P* = 0.25, *I*^2^ = 25%     Fixed
  Li et al., 2009        144                   148                      5.46 \[−9.49, 20.41\]    *P* = 0.47       *P*= 0.62, *I*^2^ = 0%       Fixed
  Wang, 2004             191                   196                      −5.57 \[−7.63, −3.51\]   *P* \< 0.00001   *P*= 0.32, *I*^2^ = 0%       Fixed
  *CRP*                                                                                                                                        
  Before excluding       405                   411                      −1.03 \[−1.76, −0.29\]   *P* = 0.006      *P* = 0.01, *I*^2^ = 62%     Random
  Cao, 2015              268                   269                      −1.08 \[−1.83, −0.33\]   *P* = 0.005      *P* = 0.010, *I*^2^ = 67%    Random
  Li et al., 2009        352                   357                      −0.77 \[−1.48, −0.06\]   *P* = 0.03       *P* = 0.04, *I*^2^ = 57%     Random
  Lv et al., 2014        336                   342                      -0.99 \[-1.71, -0.26\]   *P* = 0.008      *P* = 0.01, *I*^2^ = 66%     Random
  Meng et al., 2013      355                   361                      -1.22 \[-1.54, -0.89\]   *P* \< 0.00001   *P* = 0.36, *I*^2^ = 9%      Fixed
  Wang, 2004             399                   405                      -1.07 \[-1.83, -0.31\]   *P* = 0.006      *P* = 0.008, *I*^2^ = 68%    Random
  Wang et al., 2013      375                   381                      -0.99 \[-1.76, -0.23\]   *P* = 0.01       *P* = 0.008, *I*^2^ = 68%    Random
  Yang and Zhang, 2007   345                   351                      -1.08 \[-2.44, 0.27\]    *P* = 0.12       *P* = 0.07, *I*^2^ = 51%     Random

###### 

Adverse events reported.

  Adverse events (*n*)                            TWPs (*n* = 789)   All of control group drugs (*n* = 349)   LEF (*n* = 26)   MTX (*n* = 129)   PLB (*n* = 80)   ZQFTN (*n* = 54)   DSSRC (*n* = 60)
  ----------------------------------------------- ------------------ ---------------------------------------- ---------------- ----------------- ---------------- ------------------ ------------------
  All, *n* (%)                                    264 (33.46)        137 (39.26)                              2 (7.69)         100 (77.52)       3 (3.75)         4 (7.41)           28 (46.67)
  Gastrointestinal, *n* (%)                       208 (26.36)        63 (18.05)                               0                38 (29.46)        0                4 (7.41)           21 (35)
  Blood and lymphatic system disorders, *n* (%)   0                  5 (1.43)                                 1 (3.85)         4 (3.10)          0                0                  0
  Infection, *n* (%)                              3 (0.38)           10 (2.87)                                0                10 (7.75)         0                0                  0
  Hepatic function abnormality, *n* (%)           10 (1.27)          16 (4.58)                                1 (3.85)         12 (9.30)         1 (1.25)         0                  2 (3.33)
  Renal function abnormality, *n* (%)             0                  3 (0.86)                                 0                3 (2.33)          0                0                  0
  Skin and mucous event, *n* (%)                  17 (2.15)          20 (5.73)                                0                14 (10.85)        2 (2.5)          0                  4 (6.67)
  Irregular menstruation, *n* (%)^*∗*^            13 (2.07)          3 (1.08)                                 0                3 (2.92)          0                0                  0
  Headache, *n* (%)                               1 (0.13)           4 (1.15)                                 0                3 (2.33)          0                0                  1 (1.67)
  Angular cheilitis, *n* (%)                      7 (0.89)                                                    0                0                 0                0                  0
  Other adverse events, *n* (%)^*∗∗*^             5 (0.63)           13 (3.72)                                0                13 (10.08)        0                0                  0

*Note*. ^*∗*^The percentages of irregular menstruation were based on the calculated total number of female patients in each group. The calculation methods were based on female patients account for 79.65% of the total number. ^*∗∗*^Other adverse events including fatigue, weight loss, anemia, palpitations, haematuria, peripheral oedema, hair loss, and unbearable smell.

[^1]: Academic Editor: Toshiaki Kogure
